Volume 4, Number 4 (12-2013)                   jdc 2013, 4(4): 226-242 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

VandRajabpour F, Raoofian R, Gholamali F, Noormohammadpour P, Hashemzadeh Chaleshtori M, Tabrizi M. Basal cell carcinoma: From molecule to therapy. jdc. 2013; 4 (4) :226-242
URL: http://jdc.tums.ac.ir/article-1-5055-en.html

1- گروه ژنتیک پزشکی
2- گروه پوست
3- مرکز تحقیقات سلولی و مولکولی
4- گروه ژنتیک پزشکی , tabrizi@tums.ac.ir
Abstract:   (3849 Views)
Basal cell carcinoma (BCC) is the most common cancer in Iran and in the world and its prevalence may become equivalent to the prevalence of all other cancers combined in the future. The Hedgehog (Hh) signaling pathway has an important role in tumorigenesis of BCC. Mutations in PTCH and Smo molecules of this pathway account for 85% to 95% of sporadic BCCs and also most cases of inherited cases. Currently, several treatment methods exist for this cancer. Mohs surgery and removing the whole tumor with free margins are the most efficient way for metastatic and highly invasive BCCs. According to the latest findings, small inhibitor molecules of the Hh pathway are becoming highlighted in drug production. Vismodegib an inhibitor of Smo, was approved by the Food and Drug Administration in 2012 as a drug for metastatic and highly invasive BCCs. Therefore, strategic targeting of signaling molecules has demonstrated success and holds great potential in medicine.
Full-Text [PDF 1630 kb]   (3526 Downloads)    
Type of Study: Review | Subject: Special
Received: 2013/11/21 | Accepted: 2013/12/22 | Published: 2014/03/9

Add your comments about this article : Your username or email:
Write the security code in the box

Send email to the article author


© 2017 All Rights Reserved | Journal of Dermatology and Cosmetic

Designed & Developed by : Yektaweb